Home › Ovarian Epithelial Carcinoma › New York
Ovarian Epithelial Carcinoma clinical trials in New York
10 studies for Ovarian Epithelial Carcinoma are looking for participants at sites in New York.
Cities in New York
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Imbert Cancer Center /ID# 275634, Bay Shore
- Northwell Health Cancer Institute At Huntington /ID# 276814, Greenlawn
- Northwell Health Center for Advanced Medicine. /ID# 275641, Lake Success
- and 2 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Mineola
- Avenzo Therapeutics Recruiting Site, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251A Study of Isoquercetin in People With Ovarian Cancer
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07303894AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, The Bronx
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 21, 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University, New York
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 2, 2026 · NCT06819007A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
Recruiting
Ages 18 and older · Women · Updated Jul 1, 2026 · NCT05429970A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
- Site 0173, New York
RecruitingPhase 1
Ages 18 and older · Women · Updated Apr 7, 2026 · NCT04516447A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 1
Ages 18 and older · Women · Updated Feb 3, 2026 · NCT06469281Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Memorial Sloan Kettering, New York
- Columbia University Herbert Irving Comprehensive Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 15, 2025 · NCT04429542From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.